on EnVVeno Medical Corporation (NASDAQ:NVNO)
Positive Interim Results for enVVeno Medical’s VenoValve in SAVVE Trial
enVVeno Medical Corporation (NASDAQ: NVNO) announced positive interim results from its SAVVE U.S. pivotal trial for the VenoValve. Presented at the 2024 Society for Vascular Surgery Annual Meeting, the data highlights significant clinical improvements in venous ulcer healing.
The trial included 21 patients with 30 venous ulcers. At the one-year mark, 91% of ulcers had either fully healed or improved. Specifically, 100% of ulcers present for one year or less before surgery had completely healed. For ulcers older than one year, 89% showed full healing or improvement.
No recurrences were observed among fully healed cases. enVVeno is on track to file for FDA approval of the VenoValve in Q4 2024, with sufficient capital to fund operations through the end of 2025.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all EnVVeno Medical Corporation news